21 Jan 2021 --- Evonik’s novel omega 3 lysine complex, AvailOm, has been shown to produce faster absorption and bioavailability than a standard oil-based ethyl-ester omega 3 formulation in the first human clinical trial conducted on the product.The Germany-based chemicals company says the results could provide manufacturers with more tools to incorporate low but effective does of omega 3.
